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ABSTRACT
Background. Inherited nephrogenic diabetes insipidus (NDI) is a rare disorder characterized by impaired urinary
concentrating ability. Little clinical data on long-term outcome exists.
Method. This was a single-centre retrospective medical record review of patients with a diagnosis of NDI followed between
1985 and 2017. We collected available data on growth, weight, school performance, complications and comorbidities.
Results. We identified 36 patients with available data and a clinical diagnosis of NDI, which was genetically confirmed in 33
of them. Patients presented at a median age of 0.6 years and median length of follow-up was 9.5 years. Chief symptoms at
presentation were faltering growth, vomiting/feeding concerns, polyuria/polydipsia, febrile illness and hypernatraemic
dehydration. Median weight standard deviation scores (SDS) improved from 2.1 at presentation to 0.2 at last follow-up. In
contrast, height SDS remained essentially unchanged at 1.1 at presentation and 0.9 at last follow-up. Most patients were
treated with prostaglandin synthesis inhibitors and thiazides, yet weaned off during school age without an obvious change
in urine output. Median estimated glomerular filtration rate at last follow-up was 81 mL/min/1.73 m2. Urological
complications were noted in 15 patients, constipation in 11 and learning difficulties in 5. Median age at resolution of
nocturnal enuresis was 11 years. Estimated median daily fluid intake at median age of 13 years was 3800 mL/m2.
Conclusion. The overall prognosis in inherited NDI is favourable with regular treatment. As expected, most complications
were related to polyuria. There is an apparent loss of efficacy of medications during school age. Our data inform the
prognosis and management of patients with NDI.
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INTRODUCTION
Inherited nephrogenic diabetes insipidus (NDI) is a rare disorder
characterized by an insensitivity of the kidneys to arginine-
vasopressin (AVP) and a consequent inability to concentrate the
urine [1]. There are primary and secondary forms of inherited
NDI [2]. In primary inherited NDI, we distinguish between an X-
linked form, due to mutations in the gene encoding the vaso-
pressin type 2 receptor, namely arginine vasopressin receptor-2
(AVPR2) and an autosomal form, due to mutations in the gene
encoding the water channel aquaporin2 (AQP2). In addition to
NDI, patients with the X-linked form also have an impaired hae-
modynamic and coagulation response to AVPR2 stimulation [3].
Both forms are typically inherited in a recessive fashion,
although rare dominant cases have been described [4].
Approximately 90% of cases are due to mutations in AVPR2 and
to date more than 250 mutations have been described. As with
most rare diseases, little long-term clinical data exists to inform
management and prognosis. Previous reports have highlighted
the potential complications of flow uropathy, behavioural
abnormalities, such as attention deficit disorders as well as se-
vere developmental delay, sometimes associated with intracra-
nial calcifications [5–7]. Some of these, such as the
developmental delay and the intracranial calcification, are con-
sidered preventable by appropriate treatment. Here we review
the clinical course of patients in the tubulopathy clinic at Great
Ormond Street Hospital (GOSH) for Children NHS Foundation
Trust.
MATERIALS ANDMETHODS
We performed a retrospective review of the medical records of
patients with a clinical diagnosis of primary congenital NDI
who were followed in the specialized clinic for tubular disorders
at GOSH between 1985 and 2017. We ascertained available mo-
lecular, as well as clinical data, including symptoms and age
at presentation and last follow-up, family history, medical
treatments, growth indicators, complications, comorbidities
and biochemical parameters (plasma sodium, creatinine and
osmolality, as well as urine osmolality) at the time of presenta-
tion and at last follow-up. Patients without genetic confirm-
ation of the diagnosis were excluded from the main analysis to
maintain a clearly defined cohort. Standard deviation scores
(SDS) for anthropometric measures were calculated using
growth charts based on National Health and Nutrition
Examination Survey (NHANES), center for disease control (CDC)/
National Center for Health Statistics. Estimated glomerular fil-
tration rate (eGFR) was calculated with the Schwartz formula
modified for GOSH, using a k-value of 33 [8]. Statistical calcula-




We identified 41 patients with a clinical diagnosis of NDI. Five
patients were excluded, due to untraceable records. The re-
maining 36 patients all had genetic testing performed and the
diagnosis was confirmed in 33, of which 29 were male. Median
follow-up was 9.5 years (range 0.8–16.8) and median age at last
follow-up was 11.9 years (range 0.8–17).
Details of selected genetic and clinical data are presented in
Table 1.
Molecular details
Twenty-six patients had mutations in AVPR2 (all boys) and
seven in AQP2 (four boys, three girls) (Table 1). All were in-
herited in a recessive fashion. Mutations and selected clinical
details for some patients have been reported previously [9–12].
Presenting features
Congenital NDI was diagnosed during the first year of life in
23 (69%) patients. The median age of diagnosis was 0.6 years
(range 0.01–9). A family history of NDI was noted in 11 patients.
One patient (23.2) had a prenatal diagnosis. Chief complaints at
time of admission were faltering growth, vomiting, polyuria/
polydipsia and febrile illness with hypernatraemic dehydration
(Figure 1). Four (12%) were investigated due to a positive family
history.
Ten patients were treated for a different diagnosis before the
establishment of NDI, most commonly gastroesophageal reflux
disease (n¼ 5). A pyloric web was diagnosed in one case (26),
based on vomiting and hypernatraemia, and surgically cor-
rected. One patient (19) was given an initial diagnosis of central
DI at his local hospital based on a partial response to 1-desa-
mino-8-D-arginine vasopressin (DDAVP) (maximal urine osmo-
lality 602 mOsm/kg), but was subsequently found to have a
clinical diagnosis of partial NDI, confirmed by genetic testing.
Interestingly, a repeat DDAVP test at the age of 10 years showed
no response to DDAVP. Two premature neonates (18, 20) were
diagnosed in the neonatal intensive care unit based on polyuria.
One patient (21) presented with global developmental delay and
hypernatraemic dehydration at the age of 0.6 years. Magnetic
resonance imaging of the brain had been performed in five pa-
tients. One patient (15) showed signs suggestive of myelinolysis
after experiencing severe acute hypernatraemia in the context
of treatment with 0.9% saline [12].
Median SDS or score and range for height at presentation
was 1.06 (4.94 to 1.9) and for weight: 2.1 (8.25 to 2.6).
Weight for length (for children <3 years), SDS was 1.98 (7.5 to
2.3).
Feeding
Treatment included input from a renal dietician and an osmotic
load<15 mOsm/kg was targeted. Tube feeding was performed
in 34% (n¼ 12) of which 24% (n¼ 8) were fed via gastrostomy.
The indication for tube feeding was persistent growth failure in
all (weight<0.4th percentile for age and no evidence of catch-up
growth). Initially, a nasogastric tube was placed and, if tube
feeding was deemed necessary for several months, a gastros-
tomy was considered. Tube feeding was discontinued at a me-
dian age of 2 years (range 2–4) once growth failure had resolved
and oral intake was deemed adequate.
Medications
For drug treatment, all patients bar one (25) received thiazides
at diagnosis and 28 (84%) received an additional prostaglandin
synthesis inhibitor (PSI), mostly indomethacin (n¼ 25), or, alter-
natively, celecoxib (n¼ 2) or ibuprofen (n¼ 1). PSI was discontin-
ued in 10 (indomethacin in 9, ibuprofen in 1) because of
perceived lack of efficacy at median age 12 years (range 4–16). In
addition, it was changed to celecoxib in one patient (15, at age
3 years) due to a gastrointestinal bleed and stopped in another
one (7.1) due to concerns over renal function associated with an
obstructive uropathy (at age 12 years). Five patients (2.3, 6, 7.2,
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20 and 25) switched from indomethacin to ibuprofen due to dif-
ficulties with medication availability. One patient (25) de-
veloped nausea after commencement of celecoxib and it was
changed to ibuprofen. One patient (2.2) developed severe hydro-
nephrosis and a distended bladder with a volume of 1500 mL
and post-void residual (PVR), which was noted for a first few
months after stopping indomethacin. The drug was restarted
but without apparent change in urine volume and the hydro-
nephrosis persisted. The median daily dose of indomethacin at
the time of discontinuation due to perceived lack of efficacy
was available in eight patients and was 1.1 mg/kg (range 0.4–
1.7). Those patients continuing indomethacin (n¼ 7) were pre-
scribed at last follow-up a median daily dose of 1.4 mg/kg.
Similarly, thiazides were discontinued in eight patients at a
median age of 14 years (range 5–17). At this age, all eight
were receiving bendroflumethiazide with a median daily dose
of 0.08 mg/kg (range 0.06–0.11). In those continuing bendroflu-
methiazide (n¼ 15), the median prescribed daily dose was
0.1 mg/kg. Urine output was not formally measured before and
after stopping medications, but patients reported no apparent
change.
Amiloride was given in four patients (Table 1) to maintain
normokalaemia. Apart from these drugs, potassium chloride
was prescribed in 19% of patients. Other prescribed medications
mostly included laxatives, antacids and prokinetics. Five pa-
tients were able to stop all medications at median age of
14 years (12.563.8).
Biochemistries
Biochemistries at presentation were consistent with the clinical
diagnosis of NDI: median (range) for urine osmolality was 86
(46–177) mOsm/kg, for plasma osmolality 303 (277–359) mOsm/kg
and for plasma sodium 148 (133–177) mmol/L. Median eGFR at
presentation was 54 mL/min/1.73 m2 (range 26–140).
Interestingly, urine osmolality in patient 7.1 increased after
DDAVP to 570 mOsm/kg, consistent with a diagnosis of partial
NDI [9].
Biochemistries at last follow-up showed persistent NDI with
a median (range) urine osmolality of 84 (31–215) mOsm/kg, but
now with normal plasma values: median osmolality 292 (281–
307) mOsm/kg and sodium 143 (133–149) mmol/L.
Growth
Median SDS or z-score for weight (range) improved from: 2.1
(8.3 to 2.6) at presentation to 0.2 (2.8 to 3) at last follow-up
(Table 2). In contrast, height SDS (range) remained essentially
unchanged: 1.06 (4.94 to 1.9) at presentation and 0.9 (4.2
to 1.3) at last follow-up.
Urological problems
Urological complications were noted in 46% (n¼ 15) of patients.
Nocturnal enuresis and incomplete voiding were the most com-
mon concerns. Large bladder capacity and incomplete bladder
emptying was noted in eight patients. During follow-up of mild-
to-moderate severity, unilateral or bilateral hydronephosis was
noticed in 14 patients and 7 of these had persistence of hydro-
nephrosis and a large bladder capacity, whereas in 7 the dilata-
tion was only mild and transient (Figure 2). Resolution of
nocturnal enuresis was seen in 19 patients at a median age of
11.3 (range 5–16) years. Interestingly, one child (7.1) with partial
NDI had resolution of nocturnal enuresis with desmopressin
therapy [9]. One patient (10.1) with hydronephrosis and multiple
urinary tract infection was found to have posterior urethral
valves, and had a left nephroureterectomy and Mitrofanoff for-
mation [10]. His brother (10.2) shared the diagnosis of NDI but
had no evidence of an obstructive uropathy.
Estimated glomerular filtration rate
Median eGFR at last follow-up was 81 (range 56–129) mL/min/
1.73 m2 and was comparable between patients with AVPR2 and
AQP2 mutations (Table 2).
Fluid intake at last follow-up, as estimated by patients and/
or family was available in 28 patients. Estimated median daily
fluid intake at a median age of 13 years was 3800 mL/m2 (range
1600–9200).
Constipation
Constipation remained a concern in our cohort in 11 patients. It
was often noted during the initial years with mild-to-moderate
severity. Regular intake of laxatives was prescribed in most of
these patients.
Intelligence and school performance
One patient (21) had severe global developmental delay already
noted at his presentation at 7 months of age with faltering
growth and hypernatraemic (170 mmol/L) dehydration. Data on
learning or behaviour problems were available in 5 (17.8%) out
of 28 school-age children, who had been diagnosed with atten-
tion-deficit hyperactivity disorder (ADHD) and/or learning diffi-
culties and/or impaired concentration (Table 1).
No complaints on school performance were noted in the re-
cords of the remaining patients.
Genotype–phenotype correlation
We compared clinical parameters of the 26 patients with AVPR2
mutations to the 7 with AQP2 mutation. No significant differ-
ence was seen (see Table 2).
FIGURE 1: Symptoms at initial presentation. Shown is the frequency of the chief
complaints at presentation.
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Patients without genetic confirmation
In three patients, no mutation in AVPR2 or AQP2 could be identi-
fied: two male siblings and one female child presented at a
median age of 0.16 (range 0.01–0.16) years. Further genetic
analysis showed that both brothers had inherited the same
X-chromosome from their mother. The girl, born to consanguin-
eous parents, was homozygous at the AQP2 locus. Thus, it is pos-
sible that these three patients have non-coding mutations in
these genes, which were not assessed by the testing procedure in
the laboratory. All three were unresponsive to intravenous
DDAVP at presentation with median maximum osmolality of 97
(range 91–114) mOsm/kg, consistent with NDI. There were no
clinical features that would suggest a diagnosis of secondary NDI
[2, 13]. Median plasma sodium at presentation was 154 (150–157)
mmol/L and osmolality 309 (307–317) mOsm/kg. Of specific inter-
est was a spontaneous improvement of urinary concentrating
ability in the two brothers, with a DDAVP test at 11 and 15 years
of age showing a maximum urine osmolality of 536 and 752
mOsm/kg, respectively (Table 3).
DISCUSSION
We here report long-term clinical data on a single-centre cohort
of patients with congenital NDI. Overall, our data show a
favourable outcome: growth is in the normal range for the vast
majority of patients, although median height at follow-up was
slightly below the average at 0.9 SDS. Kidney function, as as-
sessed by eGFR at last follow-up, was within chronic kidney dis-
ease (CKD) Stages 1 or 2 in all except for Patient 12, who was
born with a single kidney.
Previous reports have highlighted the complications of NDI
with regards to intellectual function [6, 14, 15]. Unfortunately,
data on school performance were not systematically captured in
the medical records and thus may be underestimated in our
study, but intellectual and/or behavioural problems were noted
in five patients (see Table 1), mostly in the form of a diagnosis of
ADHD and/or impaired concentration and learning difficulties.
This is considerably less than in a previous report where patients
were systematically assessed and almost half had a diagnosis of
ADHD and 70% a low score on short-term memory [5]. It has been
debated whether ADHD is an intrinsic aspect of the disorder, as
there are data suggesting at least temporary expression of AVPR2
in the brain, as well as an effect of AVP on learning and memory
[16, 17]. Moreover, AVPR2 knock-out mice show altered expres-
sion of genes in the hypothalamus [18]. Alternatively, ADHD and
problems with concentration or memory may be secondary to
the constant craving for water and the frequent need to void. In
this context, it is interesting that we saw this complication only
in patients with AVPR2. Yet, this difference in the proportion of
patients with noted learning or behavioural problems was not
statistically significant between AVPR2 and AQP2 (P¼ 0.2).
Early reports on patients with NDI suggested severe intellec-
tual impairment as an almost invariant feature of the disease,
but subsequent observations indicate that this complication
can be prevented in most by adequate treatment [5, 6, 15]. The
latter is consistent with our observations here, as we saw severe
global developmental delay in only one patient (21).
Interestingly, while presenting with hypernatraemic dehydra-
tion, his features were not substantially different from other pa-
tients in this cohort. It is thus unclear whether for some reason
this patient is more susceptible to brain damage, or whether his
developmental delay is unrelated to the NDI. Brain imaging to
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Overall our data are consistent with the notion that severe
intellectual impairment can be prevented with adequate
treatment.
Yet, despite the overall favourable prognosis, patients clearly
have complications from the polyuria. Almost half of all pa-
tients had radiological evidence of a flow uropathy. While this
was only transient in some it was severe in others and associ-
ated with loss of renal cortex in one (22) (Figure 2). Similarly,
nocturnal enuresis was a common problem and resolution was
much delayed at a median age of over 11 years. Typical advice
and treatment given to patients with nocturnal enuresis, such
as decreased fluid intake before bedtime or DDAVP tablets, obvi-
ously does not work in patients with NDI.
There were no episodes of hypernatraemic dehydration after
diagnosis and start of treatment apparent from the biochemis-
try results available at GOSH. Yet, since GOSH is a pure tertiary
paediatric center without provision of primary or emergency
care, acute illnesses would have presented to the respective
local hospital and thus would not be systematically captured or
reflected in laboratory results obtained at GOSH.
Of interest is the apparent change in response to medical
treatment. Thiazide and PSI have been shown to effectively re-
duce urine output in NDI during the first few years of life
[19, 20]. Indeed, one patient (2.1) developed asymptomatic hypo-
natraemia (130 mmol/L) after commencement of indomethacin
and the drug was transiently withheld. Yet, in our experience,
FIGURE 2: Examples of flow uropathy. Shown are ultrasound images detailing flow uropathy. (A) Marked hydronephrosis of single right kidney with loss of renal cortex
in Patient 22 (at age 17 years). (B) Hydronephrosis, (C) Dilated bladder and ureter, (D) PVR in Patient 2.1 (all images at age 15 years). Hydronephrosis in this patient de-
veloped after the age of 8 years.
Table 3. Spontaneous improvement in urinary concentration in the two brothers without identified mutation
Patient
Presentation Last follow-up
Age (months) Posm (mOsm/kg) Max Uosm after DDAVP Age (years) Posm (mOsm/kg) Max Uosm after DDAVP
28.1 1.5 317 114 15.3 298 536
28.2 0.1 309 91 11.5 285 752
Shown are data on urinary concentration. Patient 28.1 presented at the age of 1 month with recurrent vomiting and hypernatraemia. His brother 28.2 was electively re-
viewed at 3 days of age due to the family history. Both received a clinical diagnosis of NDI based on the inappropriately low urine osmolality. Both showed a spontan-
eous improvement in symptoms and urinary concentration over time.
Uosm, urine osmolality; Posm, plasma osmolality.
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many patients stop medications during school age without
noticing an appreciable difference in urine output. While
Patient 2.2 developed severe hydronephrosis first noted
4 months after stopping indomethacin, this did not improve
after restarting the medication. Moreover, his last previous
ultrasound, which showed no dilatation, had been 5 years ear-
lier and thus it is likely that the hydronephrosis had developed
even before the medication was stopped and was related to vol-
untary urinary retention, reflected in his large bladder volume.
Medications were typically discontinued during teenage years,
an age in which adherence to medications is a common prob-
lem [21]. Indeed, one patient (2.3) openly admitted that he had
stopped taking the medications and in others, either the patient
or a parent had reported intermittent missed doses. Thus,
whether the apparent lack of efficacy reflects a true change in
the response to medications or mainly non-adherence cannot
be discerned from our data.
The initial management of Patient 15 with normal saline for
his dehydration and subsequent severe hypernatraemia and
encephalopathy illustrates the difficulties patients with this
rare disease encounter [12]. Most general physicians and even
paediatricians will have never have encountered a patient with
NDI before and thus follow guidelines for patients in general.
Provision of a letter or leaflet that the patient or family can pre-
sent at an emergency visit, that details the diagnosis and ex-
plains emergency management that is critical to prevent such
complications.
In conclusion, we show a generally favourable long-term
outcome and an apparent loss of efficacy of medical treatment
during school age.
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